Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Antimuscarinic Treatment on Premature Ejaculation Severity in Men With Overactive Bladder: a Prospective Comparison With Mirabegron
Sponsor: Başakşehir Çam & Sakura City Hospital
Summary
Overactive bladder (OAB) is a condition characterized by involuntary bladder contractions. Antimuscarinic drugs are commonly used to treat OAB by blocking muscarinic receptors (M2 and M3) in the bladder. These same receptors are also present in the seminal vesicles and vas deferens, which are structures involved in ejaculation. This observational study aims to evaluate whether antimuscarinic drugs used for OAB treatment have any effect on ejaculation duration and the refractory period in male patients. Male patients aged 20-50 who are prescribed antimuscarinic medication (tolterodine, propiverine) for OAB will complete validated questionnaires (IIEF, PEP, PEDT, OAB-V8) before starting treatment and at 1-month and 2-month follow-up visits. No changes will be made to the patients' standard treatment.
Official title: Evaluation of the Effects of Antimuscarinic Drugs on Ejaculation Duration and Refractory Period in Male Patients Treated for Overactive Bladder: An Observational Study
Key Details
Gender
MALE
Age Range
20 Years - 50 Years
Study Type
OBSERVATIONAL
Enrollment
40
Start Date
2026-01-15
Completion Date
2026-06-30
Last Updated
2026-08-13
Healthy Volunteers
No
Interventions
Tolterodine
Tolterodine is a competitive muscarinic receptor antagonist with relative functional selectivity for the bladder. It is prescribed as standard clinical care for overactive bladder symptoms. Dose and formulation are determined by the treating physician per routine practice. No modification to the prescribed regimen is made within the scope of this observational study.
Mirabegron (beta3-adrenoceptor agonist)
Mirabegron is a beta-3 adrenergic receptor agonist used for overactive bladder treatment. Unlike antimuscarinic agents, it does not block muscarinic receptors. It is included in this study as a comparison group to evaluate whether ejaculatory effects are specific to muscarinic receptor blockade. Prescribed as standard clinical care with no modification to treatment.
Locations (1)
Başakşehir Çam and Sakura City Hospital, Department of Urology
Istanbul, Istanbul, Turkey (Türkiye)